Last reviewed · How we verify
Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab
Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab is a Chemotherapy combination with anti-angiogenic monoclonal antibody Small molecule drug developed by Lee's Pharmaceutical Limited. It is currently in Phase 3 development for Advanced or metastatic solid tumors (specific indication dependent on phase 3 trial design).
This combination regimen uses platinum-based chemotherapy and a taxane to damage cancer cell DNA, combined with an anti-angiogenic monoclonal antibody to block tumor blood vessel formation.
This combination regimen uses platinum-based chemotherapy and a taxane to damage cancer cell DNA, combined with an anti-angiogenic monoclonal antibody to block tumor blood vessel formation. Used for Advanced or metastatic solid tumors (specific indication dependent on phase 3 trial design).
At a glance
| Generic name | Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab |
|---|---|
| Sponsor | Lee's Pharmaceutical Limited |
| Drug class | Chemotherapy combination with anti-angiogenic monoclonal antibody |
| Target | DNA (platinum agents), microtubules (paclitaxel), VEGF (bevacizumab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Cisplatin or carboplatin cross-link DNA to induce cancer cell death, while paclitaxel stabilizes microtubules to disrupt cell division. Bevacizumab is a VEGF inhibitor that prevents new blood vessel formation, starving tumors of nutrients and oxygen. Together, these agents provide complementary cytotoxic and anti-angiogenic effects against solid tumors.
Approved indications
- Advanced or metastatic solid tumors (specific indication dependent on phase 3 trial design)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Neuropathy (peripheral)
- Nausea/vomiting
- Hypertension
- Proteinuria
- Bleeding/hemorrhage
Key clinical trials
- Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826) (PHASE3)
- A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer (PHASE3)
- Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer (PHASE3)
- A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer (PHASE3)
- A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer (PHASE2, PHASE3)
- A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer (PHASE3)
- Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1) (PHASE3)
- QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab CI brief — competitive landscape report
- Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab updates RSS · CI watch RSS
- Lee's Pharmaceutical Limited portfolio CI
Frequently asked questions about Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab
What is Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab?
How does Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab work?
What is Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab used for?
Who makes Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab?
What drug class is Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab in?
What development phase is Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab in?
What are the side effects of Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab?
What does Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab target?
Related
- Drug class: All Chemotherapy combination with anti-angiogenic monoclonal antibody drugs
- Target: All drugs targeting DNA (platinum agents), microtubules (paclitaxel), VEGF (bevacizumab)
- Manufacturer: Lee's Pharmaceutical Limited — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced or metastatic solid tumors (specific indication dependent on phase 3 trial design)
- Compare: Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab vs similar drugs
- Pricing: Placebo+cisplatin/carboplatin+paclitaxel+Bevacizumab cost, discount & access